scPharmaceuticals (NASDAQ:SCPH - Get Free Report) is expected to announce its earnings results before the market opens on Wednesday, March 12th. Analysts expect the company to announce earnings of ($0.39) per share and revenue of $12.08 million for the quarter.
scPharmaceuticals Price Performance
Shares of NASDAQ:SCPH traded down $0.19 during trading on Friday, reaching $2.93. 1,962,538 shares of the company traded hands, compared to its average volume of 316,088. The company's 50 day moving average is $3.37 and its two-hundred day moving average is $3.93. The firm has a market capitalization of $146.62 million, a PE ratio of -1.54 and a beta of 0.11. The company has a quick ratio of 6.89, a current ratio of 8.08 and a debt-to-equity ratio of 1.66. scPharmaceuticals has a 52 week low of $2.91 and a 52 week high of $6.20.
Analyst Upgrades and Downgrades
A number of analysts have recently weighed in on SCPH shares. Craig Hallum cut their target price on scPharmaceuticals from $16.00 to $12.00 and set a "buy" rating for the company in a research report on Thursday, November 14th. HC Wainwright reiterated a "buy" rating and set a $18.00 target price on shares of scPharmaceuticals in a research report on Monday, March 3rd.
Check Out Our Latest Stock Report on SCPH
About scPharmaceuticals
(
Get Free Report)
scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.
Further Reading
Before you consider scPharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and scPharmaceuticals wasn't on the list.
While scPharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
